The director of Myeloma Immunotherapy at University of Pennsylvania discussed ciltacabtagene autoleucel's safety profile.
This content originally appeared on our sister site, OncLive.
OncLive spoke with Adam D. Cohen, MD, assistant professor of medicine and director, Myeloma Immunotherapy, University of Pennsylvania, to learn more about the safety profile of ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma.
Cohen discussed safety data from the phase 2 CARTITUDE-2 study (NCT04133636). The study found that the main hematologic toxicities observed with cilta-cel were similar to those reported in the phase 1/2 CARTITUDE-1 trial (NCT03548207). These included neutropenia, anemia, and thrombocytopenia, according to Cohen. These toxicities are most often associated with lymphodepletion conditioning therapy, as well as the CAR T-cell therapy itself, Cohen explains.
The rates of grade 3/4 thrombocytopenia and anemia appeared to be less than what was reported on CARTITUDE-1, and prolonged grade 3/4 cytopenias also occurred less frequently; this may be because the CARTITUDE-2 study enrolled a less heavily pretreated population, Cohen concludes.